Will FDA approve the forth dose of COVID-19 vaccine for people over 50 years old?
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
- Daiichi Sankyo/AstraZeneca’s Enhertu Shows Positive Results in Phase III DESTINY-Breast06 Clinical Trial
- Mn007 Molecules Offer Potential for Combating Streptococcus pyogenes Infection
- Popular Indian Spices Banned in Hong Kong Over Carcinogen Concerns
Will FDA approve the forth dose of COVID-19 vaccine for people over 50 years old?
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Will FDA approve the forth dose of COVID-19 vaccine for people over 50 years old?
The U.S. Food and Drug Administration (FDA) could approve a second booster of COVID-19 vaccine for Americans over 50 as early as Tuesday (29th), two U.S. officials said.
According to the report, there is growing evidence that the protection of three doses of the COVID-19 vaccine is waning, and the fourth dose will help to strengthen immunity.
As the more contagious Omicron BA.2 variant continues to spread in the U.S., there is growing concern that it could lead to another surge in cases.
Dr. Eric Topol, founder and director of the Scripps Research Institute, said he supports the plan. He said: “We have a lot of people who are at least four to six months after the third dose. Without protection against the Omicron variant, especially now that we have BA.2, the risk of hospitalization and death is very high .”
But others have questioned the plan. Critics argue that the vaccine still does a good job of protecting people from serious illness, and there is not yet enough evidence to suggest another shot is needed.
Celine Gunder, an infectious disease expert, said data from Israel showed that additional booster doses did reduce the risk of serious illness, hospitalization and death in people over 60.
But she noted that it’s unclear how long this extra protection actually lasts. Other infectious disease experts say the U.S. government should focus on getting people the main dose and first booster immunization.
Unlike previous authorizations, the FDA is not expected to recommend the second booster dose to everyone, but instead to provide an option for those who need it, the report said.
Last week, Pfizer and Moderna asked the FDA to approve a second booster dose — especially for older Americans with weakened immune protections. Pfizer is asking the FDA to authorize a fourth dose for those over 65, while Moderna is asking for authorization for those 18 and older.
Will FDA approve the forth dose of COVID-19 vaccine for people over 50 years old?
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.